Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0TV6H
|
|||
| Former ID |
DIB006781
|
|||
| Drug Name |
HuM-195-Ac-225
|
|||
| Synonyms |
HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab
Click to Show/Hide
|
|||
| Indication | Acute myelogenous leukaemia [ICD-11: 2A41; ICD-10: C92.2] | Phase 1/2 | [1] | |
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1/2 | [2] | ||
| Company |
PDL BioPharma Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloid cell surface antigen CD33 (CD33) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of Actinium Pharmaceuticals. | |||
| REF 3 | J Clin Oncol 29: 2011 (suppl; abstr 6516). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.